Introduction
Statin belongs to a medication class of 3-hydroxy-3-methylglutaryl
coenzyme A reductase (HMGCR) inhibitor. It is the most significant drug
used for lipid-lowering and cardiovascular disease
prevention1. A wide range of statin myopathy has been
reported including myalgia, myopathy, myositis, or rhabdomyolysis.
Statin-induced immune-mediated necrotizing myopathy (IMNM) is a
relatively rare side effect with an incidence of 2 or 3 of every 100,000
patients taking statins2. Many different findings help
differentiate toxic non-inflammatory effects from immune-mediated
myopathy due to statins1. We report a case of
statin-induced IMNM with oropharyngeal involvement.